We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+4.23%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.4B
AUM Growth
-$764M
Cap. Flow
-$999M
Cap. Flow %
-41.57%
Top 10 Hldgs %
44.25%
Holding
367
New
126
Increased
77
Reduced
66
Closed
85

Top Buys

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$94.4M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$24M
3
AGN
Allergan plc
AGN
+$13.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$11.9M
5
MBLY
Mobileye N.V.
MBLY
+$8.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$42.1M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$27.4M
3
AZN icon
AstraZeneca
AZN
+$13.5M
4
GILD icon
Gilead Sciences
GILD
+$11.5M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$11.1M

Sector Composition

Rank Sector Weight
1 Miscellaneous 88.65%
2 Healthcare 9.88%
3 Technology 0.55%
4 Energy 0.39%
5 Industrials 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HTWR
176
PUT
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$1.17M 0.05%
133
– –
LLY icon
177
PUT
Eli Lilly
LLY
$1.02T
$1.16M 0.05%
+160
New +$11.4K
ACHN
178
DELISTED
Achillion Pharmaceuticals
ACHN
$1.12M 0.05%
113,704
-890,483
-89% -$11.1M
AXGN icon
179
Axogen
AXGN
$2.42B
$1.11M 0.05%
+318,136
New +$1.09M
EXEL icon
180
CALL
Exelixis
EXEL
$13.9B
$1.11M 0.05%
4,319
+2,305
+114% +$5.35K
NSPR icon
181
InspireMD
NSPR
$36.1M
$1.08M 0.04%
+1
New +$3.95M
VNDA icon
182
Vanda Pharmaceuticals
VNDA
$302M
$1.05M 0.04%
+113,165
New +$1.28M
CTIC
183
CALL
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$1.04M 0.04%
575
-121
-17% -$2.72K
BDSI
184
PUT
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.03M 0.04%
+985
New +$13.5K
SKBI
185
DELISTED
SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV)
SKBI
$999K 0.04%
255,435
-58,932
-19% -$250K
XOMA
186
CALL
DELISTED
Xoma
XOMA
$996K 0.04%
137
-138
-50% -$10.1K
VIRX
187
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$993K 0.04%
+19
New +$9.59K
RNVA
188
DELISTED
Rennova Health, Inc.
RNVA
$981K 0.04%
+200
New +$1.04M
SGYPW
189
PUT
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$980K 0.04%
+2,121
New +$1.74K
PLUR icon
190
PUT
Pluri
PLUR
$14.1M
$966K 0.04%
43
+33
+330% +$7.75K
NBIX icon
191
PUT
Neurocrine Biosciences
NBIX
$15.3B
$957K 0.04%
241
-1,373
-85% -$49.1K
BCRX icon
192
CALL
BioCryst Pharmaceuticals
BCRX
$2.06B
$952K 0.04%
+1,054
New +$10.9K
KYTH
193
PUT
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$943K 0.04%
+188
New +$7.89K
RXII
194
PUT
DELISTED
GALENA BIOPHARMA INC COM
RXII
$941K 0.04%
6,772
+172
+3% +$23.9K
MNK
195
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$922K 0.04%
+7,280
New +$832K
GWPH
196
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$911K 0.04%
+100
New +$8.12K
FOCL
197
PUT
EDAP TMS S.A.
FOCL
$193M
$906K 0.04%
2,687
+2,519
+1,499% +$8.44K
SSKN
198
DELISTED
Strata Skin Sciences
SSKN
$882K 0.04%
6,863
-5,122
-43% -$506K
CSLT
199
CALL
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$841K 0.04%
+1,084
New +$9.28K
CVM.WS
200
DELISTED
Cel-Sci Corp Series S
CVM.WS
$840K 0.04%
2,624,375
-440,370
-14% -$99.3K
6 7
8
9 10

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sabby Management held 367 positions worth $2.4B, down 24% from $3.17B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management withdrew a net $999M in Q1 2015, closing 85 positions and reducing 66 holdings. Its most notable exit was Pfizer, an estimated $42.1M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, down from 90% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Sabby Management opened a new position in Tempest Therapeutics worth $4.69M.

  • Sabby Management's largest Q1 2015 buy was Tempest Therapeutics: 709 shares worth $4.69M.
  • Sabby Management added most to Allergan plc in Q1 2015, an estimated $13.8M increase.
  • Sabby Management's biggest Q1 2015 reduction was Achillion Pharmaceuticals, cutting an estimated $11.1M.
  • Sabby Management fully exited Pfizer in Q1 2015, selling an estimated $42.1M.
  • Sabby Management's ten largest holdings make up 44% of its $2.4B portfolio in Q1 2015.
  • Sabby Management opened 126 new positions and closed 85 in Q1 2015.
  • Sabby Management's portfolio value fell 24% quarter-over-quarter to $2.4B.

Based on Sabby Management's 13F filing for Q1 2015, filed 15 May 2015.